The goal of this investigational study is to evaluate if the treatment using EXOMIND(BTL-699-2) device is able to improve severity of obsessive and compulsive symptoms in adults (aged 22 and older).
The main question it aims to answer is:
Does the treatment using EXOMIND (BTL-699-2) device is able safely and efficiently reduce the severity of obsessive and compulsive behaviors?
Participants will be asked to:
* Complete six treatment visits (twelve treatment sessions)
* Complete The Yale-Brown Obsessive-Compulsive Severity Scale Second Edition Self Report Version (Y-BOCS-II SR)
* Complete Short UPPS-P Impulsive Behaviour Scale (SUPPS-P)
* Compete The Warwick-Edinburgh Mental Wellbeing Scale (WEMWBS)
* Compete The Patient Health Questionnaire-9 (PHQ-9)
* Compete Columbia Suicide Severity Rating Scale -screen version(CSSRS)
* Complete Trigger Recall Experience Questionnaire (only for participants who agree to participate in trigger recall procedure during the treatment sessions)
* Compete The Therapy Comfort Questionnaire
* Compete The Subject Satisfaction Questionnaire